Search details
1.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33989557
2.
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
Cancer
; 126(1): 86-97, 2020 01 01.
Article
in English
| MEDLINE | ID: mdl-31584722
3.
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
N Engl J Med
; 386(17): 1668-1669, 2022 04 28.
Article
in English
| MEDLINE | ID: mdl-35476655
4.
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy.
Eur J Cancer
; 198: 113506, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38184928
5.
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
J Thorac Oncol
; 19(4): 636-642, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38036250
6.
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.
Front Oncol
; 14: 1305720, 2024.
Article
in English
| MEDLINE | ID: mdl-38406805
7.
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Eur J Cancer
; 205: 114101, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38735161
8.
Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
Melanoma Res
; 33(5): 422-424, 2023 10 01.
Article
in English
| MEDLINE | ID: mdl-37534694
9.
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
J Immunother Cancer
; 11(10)2023 10.
Article
in English
| MEDLINE | ID: mdl-37865395
10.
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
Oncoimmunology
; 12(1): 2261248, 2023.
Article
in English
| MEDLINE | ID: mdl-37808404
11.
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
Eur J Cancer
; 183: 109-118, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36842413
12.
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.
Front Immunol
; 13: 1030147, 2022.
Article
in English
| MEDLINE | ID: mdl-36466910
13.
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
J Immunother Cancer
; 10(6)2022 06.
Article
in English
| MEDLINE | ID: mdl-35688560
14.
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
J Immunother Cancer
; 10(7)2022 07.
Article
in English
| MEDLINE | ID: mdl-35798536
15.
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread.
Melanoma Res
; 32(4): 260-268, 2022 08 01.
Article
in English
| MEDLINE | ID: mdl-35579680
16.
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Eur J Cancer
; 176: 121-132, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36215945
17.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
J Immunother Cancer
; 10(9)2022 09.
Article
in English
| MEDLINE | ID: mdl-36096531
18.
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
J Clin Oncol
; 40(10): 1068-1080, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-35143285
19.
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Cancer Cell
; 40(1): 88-102.e7, 2022 01 10.
Article
in English
| MEDLINE | ID: mdl-34951955
20.
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Pathology
; 54(1): 6-19, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34937664